Olaparib for DNA repair-deficient prostate cancer — one for all, or all for one?

Emmanuel S. Antonarakis

doi:10.1038/s41571-020-0395-x

Olaparib for DNA repair-deficient prostate cancer — one for all, or all for one?

Research output: Contribution to journal › Article › peer-review

Original language	English (US)
Pages (from-to)	455-456
Number of pages	2
Journal	Nature Reviews Clinical Oncology
Volume	17
Issue number	8
DOIs	https://doi.org/10.1038/s41571-020-0395-x
State	Published - Aug 1 2020
Externally published	Yes

Bibliographical note

Funding Information:
The work of E.S.A. is partially supported by NIH grants P30CA006973 and R01CA238384-A1.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access

10.1038/s41571-020-0395-x

OpenUrl availability

Full text

Cite this

@article{52e285192fad43888df853e51d83d051,

title = "Olaparib for DNA repair-deficient prostate cancer — one for all, or all for one?",

author = "Antonarakis, {Emmanuel S.}",

note = "Funding Information: The work of E.S.A. is partially supported by NIH grants P30CA006973 and R01CA238384-A1.",

year = "2020",

month = aug,

day = "1",

doi = "10.1038/s41571-020-0395-x",

language = "English (US)",

volume = "17",

pages = "455--456",

journal = "Nature Reviews Clinical Oncology",

issn = "1759-4774",